HBM Healthcare Investments
HBM Healthcare Investments AG (SIX: HBMN) is a publicly listed Swiss investment company focused on the global healthcare sector. It holds a diversified portfolio of private and publicly listed companies across human medicine, biotechnology, medical technology and diagnostics. HBM deploys capital via direct equity in private companies and equity positions in listed companies, provides active portfolio management and strategic support, and pursues value realisation through IPOs, trade sales and selective follow-on investments.
HBM Healthcare Investments
Zug, Zug, Switzerland, Europe
Services
Direct equity investments
Provides capital through direct equity investments in private healthcare companies and equity positions in publicly listed healthcare companies.
Active portfolio management and strategic guidance
Provides board-level and strategic support to portfolio companies on corporate strategy, transaction execution and market positioning.
Facilitation of exits and capital-market transactions
Supports and participates in IPOs, secondary placements and trade-sale processes for portfolio companies.
Follow-on and selective new investments
Provides follow-on financing to existing portfolio companies and makes selective new investments in healthcare-focused private companies.
Capital allocation and liquidity management
Implements shareholder distributions, par-value repayments and share buy-back programmes as part of capital allocation.
Direct equity investments
Provides capital through direct equity investments in private healthcare companies and equity positions in publicly listed healthcare companies.
Active portfolio management and strategic guidance
Provides board-level and strategic support to portfolio companies on corporate strategy, transaction execution and market positioning.
Facilitation of exits and capital-market transactions
Supports and participates in IPOs, secondary placements and trade-sale processes for portfolio companies.
Follow-on and selective new investments
Provides follow-on financing to existing portfolio companies and makes selective new investments in healthcare-focused private companies.
Capital allocation and liquidity management
Implements shareholder distributions, par-value repayments and share buy-back programmes as part of capital allocation.
Portfolio
HBM retained a stake (~9%) after the sale of the DR-0201 programme to Sanofi; transaction included a USD 600 million upfront payment plus potential milestones.
#Biopharmaceuticals / antibody therapeutics
Yellow Jersey Therapeutics (spin-off of Numab) was acquired by Johnson & Johnson for USD 1.25 billion; HBM retained a stake in Numab (reported around 7–8%).
#Biotechnology / multispecific and bispecific antibodies
HBM is a significant shareholder; participated in a EUR 45 million capital increase (HBM contributed EUR 5 million) and the holding has grown via acquisitions and revenue expansion.
#Pharmaceutical distribution / commercialisation
HBM sold part of its Sai shares during the IPO period and retained a remaining holding; the IPO and partial sale generated proceeds and reported NAV impact.
#CRDMO / contract research, development and manufacturing
HBM invested across financing rounds (reported USD ~30 million aggregate) and retained shares after the IPO; Upstream raised USD 255 million in its IPO.
#Biotechnology (inflammation / antibodies)
Neurelis licenses, develops and commercialises CNS products (e.g., VALTOCO®); referenced in HBM's portfolio overview.
#CNS products (epilepsy, neurology)
HBM retained a stake (~9%) after the sale of the DR-0201 programme to Sanofi; transaction included a USD 600 million upfront payment plus potential milestones.
#Biopharmaceuticals / antibody therapeutics
Yellow Jersey Therapeutics (spin-off of Numab) was acquired by Johnson & Johnson for USD 1.25 billion; HBM retained a stake in Numab (reported around 7–8%).
#Biotechnology / multispecific and bispecific antibodies
HBM is a significant shareholder; participated in a EUR 45 million capital increase (HBM contributed EUR 5 million) and the holding has grown via acquisitions and revenue expansion.
#Pharmaceutical distribution / commercialisation
HBM sold part of its Sai shares during the IPO period and retained a remaining holding; the IPO and partial sale generated proceeds and reported NAV impact.
#CRDMO / contract research, development and manufacturing
HBM invested across financing rounds (reported USD ~30 million aggregate) and retained shares after the IPO; Upstream raised USD 255 million in its IPO.
#Biotechnology (inflammation / antibodies)
Neurelis licenses, develops and commercialises CNS products (e.g., VALTOCO®); referenced in HBM's portfolio overview.
#CNS products (epilepsy, neurology)